Recent Updates
Recently added Catalysts

Psyence Biomedical Ltd.

PBMFDA catalysts, PDUFA dates & pipeline intelligence
$2.86
▲ +0.35 · +13.94%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PBM financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.9252W HIGH $17.47
Volume
83.10 K
Value Traded
233.57 K
Short % Float
1.8%
Days to Cover
1.0
-7.44%Week
-32.55%1 Month
-27.23%3 Month
-29.56%6 Month
-99.99%5 Year
-99.99%All Time

Cash Data

Unlock PBM cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
10.91 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
3.81 M
Float Shares
1.06 M
Insiders
72.19%
Institutions
12.42%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2b data readout
NPX5 (psilocybin product)
Adjustment Disorder in patients with cancer
Phase 2bSmall MoleculesPsychiatry
Unlock every PBM catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PBM Catalyst Timeline

Dated clinical, regulatory and corporate events for Psyence Biomedical Ltd.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Psyence Biomedical Ltd.

169Total events
5Upcoming
38Tier-1 (high impact)
2023 to 2026Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
T2Timing Guidance
Subscribe to view catalyst details
ibogaine

Event history 50

▲Timing GuidanceibogainePresentation
PsyLabs completes ibogaine regulatory readiness documentation package to support future regulatory interactions
▲Manufacturing MilestoneibogaineCMC / Inspection
TIRC enters cGMP manufacturing services agreement with Benuvia for pharmaceutical-grade ibogaine API
●Equity OfferingCorporate
Psyence Biomed II Corp. completes US$2,599,896 additional investment in PsyLabs (1,014 shares)
▲Partnership / LicenseCorporate
TIRC enters manufacturing services agreement with Benuvia for U.S. manufacture of pharmaceutical-grade ibogaine API
▲Partnership / LicenseibogaineCorporate
Psyence BioMed's TIRC enters binding term sheet with PsyLabs for exclusive U.S. ibogaine license
▲Partnership / LicenseCorporate
Psyence BioMed and PsyLabs agree to value-matched share exchange (~US$9 million each side)
●Equity OfferingCorporate
Psyence BioMed irrevocably commits US$2.4M to subscribe for 936 PsyLabs ordinary shares at US$2,564/share
●Timing GuidancePresentation
Texas Ibogaine Research Corporation (TIRC) established as dedicated U.S. subsidiary for planned ibogaine development
●Management ChangeCorporate
Texas Ibogaine Research Corporation (TIRC) established as dedicated U.S. subsidiary
●Management ChangeCorporate
Dr. John Thorne appointed project lead of Texas Ibogaine Research Corporation
Unlock the full PBM catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PBM actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all PBM historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 88%
Micro Cap
(rank 636 of 723)
Percentile Rank
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Psilocybin therapy Small MoleculesNCT07072728Adjustment DisorderPhase 2 RECRUITING 87Dec 30, 2027
Unlock the PBM pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every PBM program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every PBM trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PBM insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full PBM insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in PBM for Q3 2026.
Unlock every fund holding PBM
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PBM
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see PBM ownership
Insider and institutional ownership, quarter by quarter.

PBM Short Interest

Shares sold short, counted twice a month.

1.8%
Short % of Float
of tradable shares sold short
19.1K
Shares Sold Short
-6.1% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
58.0K
Avg Daily Volume
the average used for days to cover
Unlock PBM short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock PBM option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PBM option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PBM options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PBM ranks across every disease it competes in

Competitive Position is a premium feature
See how PBM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PBM News

PBM
Oct 21, 2026
PBMGeneral
▲ +6.6%on this news

Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met

Psyence BioMed invested $2.6 million in PsyLabs after meeting two milestones. The company completed ibogaine regulatory documentation and signed a cGMP manufacturing deal with Benuvia. This investment raises Psyence’s stake in PsyLabs to 43.37 percent. The move supports the firm’s U.S. ibogaine development program.

Read more →
PBM
Oct 5, 2026
PBMGeneral

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Psyence BioMed's subsidiary, Texas Ibogaine Research Corporation, has partnered with Benuvia Operations to manufacture pharmaceutical-grade ibogaine in the U.S. This collaboration aims to establish a compliant manufacturing pathway under DEA regulations. The partnership is part of Psyence's strategy to support clinical programs for mental health and substance use disorders, leveraging Benuvia's extensive manufacturing capabilities.

Read more →
PBM
Sep 28, 2026
PBMFDA Updates

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Psyence BioMed's subsidiary, Texas Ibogaine Research Corporation, has secured an exclusive U.S. license for pharmaceutical-grade ibogaine from PsyLabs. This agreement provides TIRC with rights to develop and distribute ibogaine, contingent on a definitive agreement by November 30, 2026. The collaboration aims to expedite the development of ibogaine drug candidates to meet mental health needs.

Read more →
PBM
Sep 23, 2026
PBMGeneral

Psyence BioMed Announces Strategic Ibogaine Investment

Psyence BioMed has announced a strategic investment of up to $5 million in PsyLabs, along with a value-matched share exchange valued at approximately $9 million. This initiative aims to support the development of pharmaceutical-grade ibogaine for a potential clinical trial targeting Opioid Use Disorder in Texas. The establishment of the Texas Ibogaine Research Corporation will facilitate regulatory and clinical activities for the U.S. program.

Read more →
PBM
Sep 14, 2026
PBMGeneral
▲ +11.1%on this news

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Psyence BioMed has established the Texas Ibogaine Research Corporation to coordinate U.S. development of pharmaceutical-grade ibogaine. This entity aims to streamline supply, regulatory engagement, and clinical development efforts. The formation follows recent U.S. policy developments promoting ibogaine research, with plans for future licensing and regulatory activities. Jody Aufrichtig will lead TIRC as CEO.

Read more →
PBM
Aug 19, 2026
PBMFDA Updates
▼ -8.3%on this news

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Psyence BioMed has welcomed the U.S. government's announcement to accelerate ibogaine development, aligning with their pharmaceutical platform. President Trump highlighted the submission of the original ibogaine IND application by the University of Miami, which could expedite clinical research. The company is actively engaging with stakeholders to advance ibogaine's clinical development.

Read more →
PBM
May 15, 2026
PBMGeneral

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Ltd. announced a strategic engagement initiative in the U.S. to promote GMP ibogaine research and manufacturing. The company's leadership will meet with key stakeholders to discuss regulatory considerations and scientific infrastructure. This initiative follows recent U.S. policy changes supporting psychedelic research, and Psyence aims to educate on compliant ibogaine production.

Read more →
PBM
Apr 23, 2026
PBMPhases

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical Ltd. has commenced patient dosing in its Phase IIb clinical trial assessing NPX-5, a psilocybin treatment for Adjustment Disorder in cancer patients receiving palliative care. This trial marks the first significant human evaluation of NPX-5 and aims to evaluate its safety and efficacy across multiple sites in Australia. The company seeks to generate critical clinical data to inform future development and regulatory pathways while addressing a significant psychological need in this patient population.

Read more →
PBM
Apr 20, 2026
PBMGeneral
▲ +48.7%on this newsshared move

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence Biomedical Ltd. has established itself as the only licensed supplier of pharmaceutical-grade ibogaine by developing a vertically integrated platform for sourcing, manufacturing, and supplying ibogaine. The company has positioned itself to support the scientific and clinical research community as regulatory interest in ibogaine grows. By securing direct access to the natural source of ibogaine in Africa and maintaining a GMP-compliant inventory, Psyence aims to address the existing supply gaps in the market. Their capabilities will enable continued research and potential commercialization of ibogaine-based therapies.

Read more →
PBM
Apr 17, 2026
PBMFDA Updates
▲ +29.5%on this news· ran to +93% by day 1shared move

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed has welcomed reports of an upcoming U.S. executive order aimed at evaluating the safety and therapeutic potential of ibogaine, a compound thought to aid in treating PTSD and addiction. The move is seen as a necessary step toward regulated research in areas with limited treatment options. The company emphasizes the importance of controlled clinical research and has also established a GMP-compliant manufacturing presence for ibogaine. With increased interest in ibogaine, Psyence aims to support scientific progress through ethical sourcing and a robust supply chain.

Read more →
PBM
Apr 8, 2026
PBMPhases

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Psyence Biomedical Ltd. announced the expansion of its Australian clinical site network from three to five sites, including the addition of Ramsay Health Care and NeuroCentrix. This expansion is aimed at strengthening recruitment and accelerating enrollment for its ongoing Phase IIb clinical trial evaluating natural psilocybin for treating Adjustment Disorder in cancer patients. The company's move is expected to broaden its operational efficiency and support patient dosing. CEO Jody Aufrichtig emphasized the importance of this growth for generating meaningful clinical data.

Read more →
PBM
Mar 11, 2026
PBMGeneral

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Psyence BioMed has advanced its vertically integrated pharmaceutical platform through a strategic investment in PsyLabs, enhancing its manufacturing and supply chain capabilities. The company has achieved a key milestone by exporting its first clinical trial product to Australia. Psyence BioMed emphasizes disciplined capital allocation and aims for sustainable growth while navigating the evolving psychedelic therapeutics market.

Read more →
PBM
Mar 3, 2026
PBMPhases

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Psyence BioMed has successfully exported its GMP-manufactured psilocybin product NPX-5 to Australia for a Phase IIb clinical trial. This trial aims to evaluate the efficacy of natural psilocybin in treating Adjustment Disorder in cancer patients. The company emphasizes its commitment to quality and regulatory compliance while pioneering the use of nature-derived psychedelics in mental health care.

Read more →
PBM
Feb 20, 2026
PBMGeneral

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs exercised its put option, enabling a strategic equity investment where Psyence will acquire shares in PsyLabs. This exercise aims to strengthen the collaboration between the two companies, enhancing Psyence's access to high-quality psychedelic manufacturing resources. The transaction involves a Share-for-Share Exchange, resulting in PsyLabs obtaining roughly 49.98% ownership of Psyence's common shares. While this aligns with Psyence's long-term growth objectives, it poses risks of dilution for existing shareholders and significant influence over governance.

Read more →
PBM
Feb 17, 2026
PBMGeneral
▼ -9.7%on this newsshared move

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Psyence Biomedical Ltd. announced the results of its Annual and Special Meeting of Shareholders held on February 12, 2026. Shareholders approved all proposed business matters, including the election of directors and the appointment of auditors. Additionally, they authorized the board to consolidate shares at a ratio of up to 250:1, pending regulatory approvals.

Read more →
PBM
Feb 13, 2026
PBMGeneral
▲ +10%on this newsshared move

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Psyence Biomedical Ltd. has ratified a put option agreement with PsyLabs, allowing for a potential equity investment in the company. This agreement is part of a strategic relationship that enhances Psyence's access to PsyLabs' advanced manufacturing capabilities for pharmaceutical-grade psychedelics. The partnership aims to streamline Psyence's commercialization efforts and assures a reliable supply of these compounds for clinical and commercial programs. However, the success of this agreement hinges on PsyLabs' continued operational and regulatory compliance.

Read more →
PBM
Feb 13, 2026
PBMGeneral
▲ +10%on this newsshared move

BioMed Approves a Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most

Psyence BioMed has ratified a Put Option Agreement with PsyLabs, which allows PsyLabs to require Psyence to make an equity investment in exchange for access to its manufacturing capabilities. This agreement is designed to secure a reliable supply of pharmaceutical-grade psychedelics as Psyence advances its commercialization strategy. The partnership positions Psyence to mitigate risks related to regulatory and supply-chain challenges, enabling more secure planning for future clinical programs. The arrangement also preserves the company's financial flexibility while aiming to strengthen their product pipeline.

Read more →
PBM
Feb 11, 2026
PBMGeneral
▼ -6.9%on this newsshared move

Psyence BioMed Announces Settlement of Shareholder Litigation

Psyence Biomedical Ltd. has announced a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd. The settlement includes a payment of $1.5 million to KAOS and a retraction of the allegations made against the company. While the company denies any wrongdoing, it opted for the settlement to avoid further litigation and associated costs.

Read more →
PBM
Jan 28, 2026
PBMGeneral
▲ +22%on this news

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split

Psyence Biomedical Ltd. has announced the effective date for its 1-for-6.25 reverse stock split, which will take effect on February 2, 2026. This decision follows earlier Board approvals for share consolidations and aims to enhance the company's trading performance. The total number of issued shares will decrease significantly, and there may be some impact on shareholders who hold shares through brokers. The company continues to focus on psychedelic-based therapeutics and its Nasdaq listing under the symbol 'PBM'.

Read more →

About Psyence Biomedical Ltd.

12 employees psyence.com
BIOPHARMAWATCH ELITE
Trade the next PBM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime